Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)

NCT02227875 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

560

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: Mylan's insulin glargine
DRUG: Lantus®

Sponsor

Mylan Inc.

Collaborators

[object Object]